ENDRA Life Sciences (NDRA) Expected to Announce Quarterly Earnings on Tuesday

ENDRA Life Sciences (NASDAQ:NDRAGet Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect ENDRA Life Sciences to post earnings of ($4.08) per share for the quarter.

ENDRA Life Sciences (NASDAQ:NDRAGet Free Report) last announced its earnings results on Monday, March 31st. The company reported ($9.40) EPS for the quarter, missing the consensus estimate of ($4.10) by ($5.30). On average, analysts expect ENDRA Life Sciences to post $-47 EPS for the current fiscal year and $-15 EPS for the next fiscal year.

ENDRA Life Sciences Stock Performance

Shares of NDRA stock opened at $3.26 on Monday. The company has a market capitalization of $1.83 million, a P/E ratio of 0.00 and a beta of 0.19. The company’s 50 day moving average price is $4.27 and its two-hundred day moving average price is $5.21. ENDRA Life Sciences has a 52 week low of $2.90 and a 52 week high of $602.00.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets dropped their target price on shares of ENDRA Life Sciences from $75.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, April 21st.

Read Our Latest Stock Analysis on ENDRA Life Sciences

ENDRA Life Sciences Company Profile

(Get Free Report)

ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.

Read More

Earnings History for ENDRA Life Sciences (NASDAQ:NDRA)

Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.